Lead Product(s) : OLX72021
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLX72021 acts to suppress the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor (AR)
Product Name : OLX72021
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : OLX72021
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LEM-S401
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars, also claims to minimize the incidence of scars and the ability to remove pre-existing scars, increasing quality of life for patients.
Product Name : LEM-S401
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : LEM-S401
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BRE-AD01
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRE-AD01 is produced from stem cells (named 'BxC') stimulated with a specified, well-defined clinical available compound, which comprised the backbone of Brexogen's technology.
Product Name : BRE-AD01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : BRE-AD01
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable